Evaluation of Asthma and Allergic Rhinitis Risks in Patients with Atopic Dermatitis Undergoing Treatment with Biologics and JAK Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials - Summary - MDSpire
Advertisement
Evaluation of Asthma and Allergic Rhinitis Risks in Patients with Atopic Dermatitis Undergoing Treatment with Biologics and JAK Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
To compare the risks of asthma and allergic rhinitis adverse events associated with different biologics and JAK inhibitors in patients with atopic dermatitis, emphasizing the importance of these comparisons for clinical decision-making.
Key Findings:
A total of 26 RCTs were included after screening 5581 articles, highlighting the need for careful consideration of treatment options.
Dupilumab treatment was associated with a reduced incidence of new or worsening allergic events compared to placebo, suggesting its potential as a safer option.
The risk of asthma and allergic rhinitis associated with other biologics and JAK inhibitors remains to be fully determined, indicating a gap in current knowledge.
Interpretation:
The findings suggest that while dupilumab may lower the risk of allergic events, further investigation is needed to clarify the safety profiles of other systemic treatments for AD, including specific areas of focus for future research.
Limitations:
Exclusion of non-RCT designs and studies lacking adverse event data may limit the generalizability of the findings.
Potential publication bias and small-study effects not fully addressed could skew the results.
Conclusion:
This systematic review and network meta-analysis provides insights into the comparative risks of asthma and allergic rhinitis in AD patients treated with biologics and JAK inhibitors, emphasizing the need for personalized treatment strategies based on these findings.
